scholarly journals Everyday protective buffering predicts intimacy and fear of cancer recurrence in couples coping with early‐stage breast cancer

2018 ◽  
Vol 28 (2) ◽  
pp. 317-323 ◽  
Author(s):  
Christine Perndorfer ◽  
Emily C. Soriano ◽  
Scott D. Siegel ◽  
Jean‐Philippe Laurenceau
Keyword(s):  
Breast Cancer ◽  
Early Stage ◽  
Cancer Recurrence ◽  
Early Stage Breast Cancer ◽  
Fear Of Cancer Recurrence ◽  
Protective Buffering ◽  
Fear Of Cancer ◽  
Couples Coping

scholarly journals Patients’ and Oncologists’ Perspectives On A Novel Clinician Led Fear of Cancer Recurrence (CIFeR) Intervention

2021 ◽  
Author(s):  
Anastasia Serafimovska ◽  
Jia Liu ◽  
Jane Beith ◽  
Phyllis Butow
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Survivors ◽  
Early Stage ◽  
Cancer Recurrence ◽  
Fear Of Cancer Recurrence ◽  
Cultural Issues ◽  
Prognostic Information ◽  
Clinically Significant ◽  
Fear Of Cancer ◽  
Survey Responses

Abstract PurposeDespite strong demand from breast cancer survivors, there is a dearth of flexibly delivered, accessible psychological interventions addressing fear of cancer recurrence (FCR). This study aimed to explore patients’ and clinicians’ perspectives concerning the experience, utility and barriers to a novel clinician-led FCR intervention (CIFeR).MethodsTwenty female participants (Mean age; 59.8, SD = 11.43), diagnosed with early-stage breast cancer (mean years since diagnosis = 2.8, SD = 1.37 years) participated in telephone interviews, and their five oncologists completed a semi-structured electronic survey. Thematic qualitative analyses were performed on interview transcripts and survey responses.ResultsFindings indicated both patients and clinicians were positive about CIFeR with perceived cognitive, behavioural and emotional benefits of CIFeR most pronounced for patients with clinically significant FCR. All patients, however, found that receiving CIFeR (especially the tailored prognostic information) from their oncologists with whom they had a long-standing relationship, added a much-needed human element to addressing FCR. Similarly, clinicians valued CIFeR as a clear and consistent way to address unmet needs around FCR, with some barriers around time, language and cultural issues noted.ConclusionOverall, all participants perceived CIFeR as strongly beneficial in reducing FCR and related worries, thus warranting further evaluation of its utility in clinical practice.This study was prospectively registered on the 2nd of October, 2018 in the Australian New Zealand Clinical Trials Registry (ACTRN12618001615279).

scholarly journals Perilla Oil and Bifidobacterium for Alleviating Fear of Cancer Recurrence in Breast Cancer Survivors: Study Protocol for a Three-Arm Phase II Randomized Controlled Study (POB Study)

2021 ◽  
Vol 4 (3) ◽  
pp. 46
Author(s):  
Yohei Sasaki ◽  
Mina Honyashiki ◽  
Takayuki Kinoshita ◽  
Akira Matsui ◽  
Ayako Nakashoji ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Survivors ◽  
Phase Ii ◽  
Study Protocol ◽  
Breast Cancer Survivors ◽  
Cancer Recurrence ◽  
Fear Of Cancer Recurrence ◽  
Randomized Controlled ◽  
Perilla Oil ◽  
Fear Of Cancer

The fear of cancer recurrence (FCR) is the most common and most severe unmet need among cancer survivors. Safe treatments for the FCR that are easily disseminated are greatly needed. Our primary aim is a preliminary evaluation of the efficacy and effect size of perilla oil, which is rich in omega-3 fatty acids, and Bifidobacterium, a probiotic, on FCR in breast cancer survivors after the completion of chemotherapy. This study has been planned as an exploratory clinical study (phase II) and will be conducted as a three-arm, 12-week parallel group, masked-rater randomized controlled trial. Fifteen participants will be randomized with 1:1:1 allocation to receive Bifidobacterium plus perilla oil, Bifidobacterium alone, or no intervention (control). Interventions will end within 12 weeks after the random allocation of each participant. The participants will be outpatients with invasive breast cancer aged 20 years or older whose chemotherapy was completed at least 6 months before registration; hormone therapy may be ongoing. The primary outcome will be severity of FCR at 12 weeks assessed by masked raters using the 4-item Concerns about Recurrence Scale concerning overall fear of recurrence. The study protocol for the current study is registered in the Japan Registry of Clinical Trials (jRCTs031200029).

scholarly journals Understanding Women’s Choice of Mastectomy Versus Breast Conserving Therapy in Early-Stage Breast Cancer

2017 ◽  
Vol 11 ◽  
pp. 117955491769126 ◽  
Author(s):  
Jeffrey Gu ◽  
Gary Groot ◽  
Lorraine Holtslander ◽  
Rachel Engler-Stringer
Keyword(s):  
Breast Cancer ◽  
Early Stage ◽  
Cancer Recurrence ◽  
Breast Conserving Therapy ◽  
Study Data ◽  
Size Perception ◽  
Early Stage Breast Cancer ◽  
Decision Making Process ◽  
Interpretive Description ◽  
Compare And Contrast

Objective: To identify factors that influence Saskatchewan women’s choice between breast conserving therapy (BCT) and mastectomy in early-stage breast cancer (ESBC) and to compare and contrast underlying reasons behind choice of BCT versus mastectomy. Methods: Interpretive description methods guided this practice-based qualitative study. Data were analyzed using thematic analysis and presented in thematic maps. Results: Women who chose mastectomy described 1 of the 3 main themes: worry about cancer recurrence, perceived consequences of BCT treatment, or breast-tumor size perception. In contrast, women chose BCT because of 3 different themes: mastectomy being too radical, surgeon influence, and feminine identity. Conclusions: Although individual reasons for choosing mastectomy versus BCT have been discussed in the literature before, different rationale underlying each choice has not been previously described. These results are novel in identifying interdependent subthemes and secondary reasons for each choice. This is important for increased understanding of factors influencing a complicated decision-making process.

scholarly journals Post-diagnosis weight gain and breast cancer recurrence in women with early stage breast cancer

2006 ◽  
Vol 99 (1) ◽  
pp. 47-57 ◽  
Author(s):  
Bette J. Caan ◽  
Jennifer A. Emond ◽  
Loki Natarajan ◽  
Adrienne Castillo ◽  
Erica P. Gunderson ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Weight Gain ◽  
Early Stage ◽  
Cancer Recurrence ◽  
Early Stage Breast Cancer ◽  
Breast Cancer Recurrence

scholarly journals Fear of Cancer Recurrence Is Highly Prevalent and Linearly Associates With Anxiety and Depression in Chinese Breast Cancer Patients

2022 ◽  
Author(s):  
Zhensheng Li ◽  
Yue Li ◽  
Yunjiang Liu ◽  
Jun Zhang ◽  
Xiaohui Ji ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Recurrence ◽  
Depression Score ◽  
Fear Of Cancer Recurrence ◽  
Anxiety And Depression ◽  
Breast Cancer Patients ◽  
Distress Screening ◽  
Reference Analysis ◽  
Cross Sectional ◽  
Fear Of Cancer

Abstract Objective: To characterize the fear of cancer recurrence (FCR) and its relationship with anxiety and depression and quality of life (QoL) among Chinese breast cancer (BC) patients in China. Methods: Patients completed the questionnaires of QLQ-C30, QLQ-BR32 and HAD to assess FCR, QoL, anxiety and depression before radiotherapy. A cross-sectional analysis was performed. Chi-square and non-parametric tests and multivariate ordinal logistic regressions (mOLR) were utilized for reference analysis. Final covariates included age, BMI, TNM, surgery, chemotherapy, pain, and sleep disturbance. Results: From July 2015 to December 2016, 463 patients were prospectively enrolled. Their age mean (range) were 47 (19 - 89) years old. In total, 327 patients (70.6%) reported having FCR ‘a little bit’ (51.2%), ‘some’ (12.1%) and ‘very much’ (7.3%) in the past week. FCR severity ordered above (incl. ‘no’) was associated with anxiety score (median 1.5, 5.0, 7.0, 8.5 and level (‘abnormal’ rate 0%, 3.4%, 12.5%, 26.5%), depression score (median 2.0, 4.0, 6.0, 6.5) and level (‘abnormal’ rate 2.2%, 3.4%, 5.4%, 17.7%) (all p<0.001). mOLR showed that compared to ‘no’, three higher levels of FCR were associated with one level increase of anxiety with OR (p) as 1.983 (0.076), 4.291 (0.001), 8.282 (<0.001) and depression with OR (p) as 1.903 (0.062), 2.262 (0.065), 4.205 (0.004), respectively. FCR severity also was inversely associated with most QoL function scores (p<0.001). Conclusions: FCR was prevalent in Chinese BC patients and linearly associated with anxiety, depression and low QoL. It seems that a single-item question for FCR is a valid surrogate tool for distress screening in this population.

Sign in / Sign up

Export Citation Format

Share Document